As of November 7, 2026, TriSalus Life Sciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 29, 2026, naming 1 departure. The latest filing names Jodi Devlin, leaving (Form 8-K, April 29, 2026).
Who owns TriSalus Life Sciences, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like TriSalus Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
TriSalus Life Sciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as TriSalus Life Sciences, Inc. files it.
Also on the record for TriSalus Life Sciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 7, 2026 | Stake report, Schedule 13G/A, by First Light Asset Management, LLC | 10.74% of the class | 5%+ stakes | Source |
| May 20, 2026 | Stake report, Schedule 13G/A, by James J. Pallotta | 5.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by First Light Asset Management, LLC | 8.75% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by Utmost Group PLC | 5.71% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 4.09% of the class | 5%+ stakes | Source |
| November 3, 2025 | Stake report, Schedule 13G, by Utmost Group PLC | 6.79% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13G, by Utmost Group PLC | 0.0529% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 5.29% of the class | 5%+ stakes | Source |
| August 4, 2025 | Stake report, Schedule 13D/A, by Frankenius Equity AB | 14% of the class | 5%+ stakes | Source |
| August 1, 2025 | Stake report, Schedule 13D/A, by Mats Wahlstrom | 6% of the class | 5%+ stakes | Source |
| May 8, 2025 | Form D, private offering | $22M sold | Form D page | Source |
| December 30, 2024 | Form D, private offering | $1000K sold | Form D page | Source |
Selling to them or working with them? See who runs TriSalus Life Sciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on TriSalus Life Sciences, Inc. and the records around it.
TriSalus Life Sciences, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)
Watch TriSalus Life Sciences, Inc.
Get an email when TriSalus Life Sciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on TriSalus Life Sciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TriSalus Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TriSalus Life Sciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-29 | Out | 2026-10-01 | 8-K, 2026-04-29 |
New leaders reset buying decisions — get the Full Report on TriSalus Life Sciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at TriSalus Life Sciences, Inc., with the record behind each one.
Find candidates like senior executive at TriSalus Life Sciences, Inc.Every change, in the filing's words
Departing: Jodi Devlin, effective 2026-10-01
On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the "Company") of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.
- The Company is grateful for Ms. Devlin's contributions.
- As previously announced on April 7, 2026, the Company appointed Dr. Richard Marshall to Chief Medical Officer of the Company, effective June 29, 2026.
Tools for this story
Each opens in a new tab, filled in for TriSalus Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.